Predicting blood clot risks in cancer patients

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to investigate thrombin generation and its role in predicting thromboembolic events in patients with solid tumors at high risk for thrombosis. Biological blood samples will be collected monthly for a year following the initiation of systemic treatment to analyze coagulation factors. The study focuses on understanding the hypercoagulable state associated with cancer and how it contributes to venous thromboembolism (VTE), a significant complication in these patients. By identifying patients at risk, the study seeks to improve management and outcomes for cancer patients undergoing treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Patient aged \> 18 years,
2. Patient with a solid cancer at high risk of thrombosis, whether metastatic or not (lung, pancreatic, gastric or glioblastoma cancers)1,
3. Patients who have not received any systemic treatment for their cancer,
4. An informed patient who does not object to the use of data for research purposes and who has consented to the collection, use and storage of biological samples.

Exclusion Criteria:

1. Patient who has had a VTE in the 12 months preceding the diagnosis of cancer,
2. Patient on low molecular weight heparins, standard unfractionated heparins and anti-vitamin K2,
3. Women who are pregnant, likely to become pregnant or who are breast-feeding,
4. Persons deprived of their liberty, under court protection, under curators or under the authority of a guardian,
5. Unable to undergo medical monitoring of the trial for geographical, social or psychological reasons.

Where it's running

• Institut de Cancerologie de L'Ouest
  Saint-Herblain, France Recruiting

Study contacts

• Principal investigator: Judith RAIMBOURG, MD — Institut de Cancerologie de L'ouest
• Study coordinator: Armelle LEFRANCOIS
• Email: armelle.lefrançois@ico.unicancer.fr
• Phone: +33240679727

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Imaging with 89Zr-DFO-YS5 to detect cancer

  This study tests a new PET radiotracer, 89Zr-DFO-YS5, to see if it can show cancer sites in adults with nerve sheath tumors, bladder cancer, or other solid tumors.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT07664397

• MSK-TCR5 in adults with advanced solid tumors that have KRAS/HRAS/NRAS G12D

  This study tests MSK-TCR5 to see if it is safe for adults with advanced solid tumors carrying a KRAS, HRAS, or NRAS G12D mutation.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07638371

• Using 18F-TRX to image solid tumors

  This trial tests whether the 18F-TRX PET tracer can detect tumors in adults with advanced solid tumors such as high‑grade glioma, clear cell renal cell carcinoma, or metastatic castration‑resistant prostate cancer.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT06942104

• PET imaging with [89Zr]DFO-starPEG for solid tumors

  We will test a new PET imaging tracer called [89Zr]DFO-starPEG in adults with measurable solid tumors to see if it highlights tumor uptake and is safe.

  Recruiting Phase 1 University of California, San Francisco · San Francisco, California · NCT06894745

• ImmunoPET imaging for solid tumors targeting Trop2

  This study is testing a new imaging method to see if it can help diagnose solid tumors like bladder and prostate cancer better than current methods.

  Recruiting Phase 2/3 RenJi Hospital · Shanghai · NCT06851663

• Testing DM002 in patients with advanced solid tumors

  This study is testing a new drug called DM002 to see if it is safe and effective for people with advanced solid tumors.

  Recruiting at 7 sites Phase 1/2 Doma Biopharmaceutical（Suzhou）Co., Ltd. · San Francisco, California and 6 other locations · NCT06751329

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.